Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study of DB-3Q for the Treatment of Medically Refractory Crohn's Disease

NCT07625293 is registered in ClinicalTrials.gov with Direct Biologics, LLC as lead sponsor.

NCT NCT07625293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07625293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study of DB-3Q for the Treatment of Medically Refractory Crohn's Disease
Lead sponsor
Direct Biologics, LLC
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2026
Completion date
December 31, 2027
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease (cd)